CRBP - Corbus Pharmaceuticals Holdings Inc Stock Price, Fair Value and News

$19.21-0.70 (-3.52%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CRBP RSI Chart

CRBP Valuation

Market Cap

231.4M

Price/Sales (Trailing)

266.5

CRBP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CRBP Fundamentals

CRBP Revenue

Revenue (TTM)

881.7K

CRBP Earnings

Earnings Growth (Yr)

-13.81%

Earnings Growth (Qtr)

-44.91%

CRBP Price Action

Last 7 days

-8.2%

Last 30 days

-65.3%

Last 90 days

-61.8%

Trailing 12 Months

196.5%

CRBP Profitability

CRBP Financial Health

Current Ratio

6.18

CRBP Investor Care

Shares Dilution (1Y)

172.26%

CRBP Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	0	0	0
2020	0	0	0	3.9M
2019	0	0	0	36.1M
2018	0	0	0	4.8M
2017	0	0	0	2.4M
2016	0	0	0	1.9M
2015	0	0	0	648.4K

Get all data in R, Python etc through our Historical Stock Data APIs

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFÃƒÆ’Ã…Â¸ expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CEO	Dr. Yuval Cohen Ph.D.
WEBSITE	corbuspharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	33

Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions

What is the ticker symbol for Corbus Pharmaceuticals Holdings Inc? What does CRBP stand for in stocks?

CRBP is the stock ticker symbol of Corbus Pharmaceuticals Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corbus Pharmaceuticals Holdings Inc (CRBP)?

As of Fri Oct 04 2024, market cap of Corbus Pharmaceuticals Holdings Inc is 231.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers.

Is Corbus Pharmaceuticals Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether CRBP is over valued or under valued. Whether Corbus Pharmaceuticals Holdings Inc is cheap or expensive depends on the assumptions which impact Corbus Pharmaceuticals Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBP.

What is Corbus Pharmaceuticals Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 04 2024, CRBP's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 266.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBP PE ratio will change depending on the future growth rate expectations of investors.